Lilly's stomach cancer drug meets main goal, but fails to improve survival rate

(Reuters) - Eli Lilly& Co said on Friday a late-stage trial testing its drug, Cyramza, as a gastric cancer treatment met the main goal of preventing the disease from advancing, but failed its secondary target of improving overall survival rates.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news